Prognostic factors for survival in metastatic renal cell carcinoma patients with brain metastases receiving targeted therapy
| Autor: | Sevil Bavbek, Ahmet Bilici, Zeki Gokhan Surmeli, Leyla Ozer, Ibrahim Yildiz, Mehmet Ali Kaplan, Fatih Selcukbiricik, Nazim Serdar Turhal, Deniz Tural, Dogan Koca, Ibrahim Vedat Bayoglu, Mert Basaran, Tulay Akman, Yasar Yildiz, Mukremin Uysal, Nuri Karadurmus, Ozgur Tanriverdi, Ozan Yazici |
|---|---|
| Přispěvatelé: | Yildiz, Ibrahim, Ozer, Leyla Acibadem Univ, Atakent Hosp, Dept Med Oncol, Istanbul, Turkey, Bilici, Ahmet Istanbul Medipol Univ, Dept Med Oncol, Istanbul, Turkey, Karadurmus, Nuri Gulhane Mil Med Acad, Dept Med Oncol, Ankara, Turkey, Tural, Deniz Bakirkoy Educ & Res Hosp, Dept Med Oncol, Istanbul, Turkey, Kaplan, Mehmet A. Dicle Univ, Dept Med Oncol, Diyarbakir, Turkey, Akman, Tulay Izmir Tepecik Training & Res Hosp, Dept Med Oncol, Izmir, Turkey, Bayoglu, Ibrahim, V Sakarya Univ, Dept Med Oncol, Sakarya, Turkey, Uysal, Mukremin Afyon Kocatepe Univ, Dept Med Oncol, Afyon, Turkey, Yildiz, Yasar Izmir Katip Celebi Univ, Ataturk Training & Res Hosp, Dept Med Oncol, Izmir, Turkey, Tanriverdi, Ozgur Mugla Sitki Kocman Univ, Dept Med Oncol, Mugla, Turkey, Yazici, Ozan Ankara Numune Training & Res Hosp, Dept Med Oncol, Ankara, Turkey, Surmeli, Zeki Ege Univ, Tulay Aktas Oncol Hosp, Dept Med Oncol, Izmir, Turkey, Turhal, Nazim Serdar Anadolu Med Ctr, Dept Med Oncol, Istanbul, Turkey, Bavbek, Sevil Amer Hosp, Dept Med Oncol, Istanbul, Turkey, Selcukbiricik, Fatih Koc Univ Hosp, Dept Med Oncol, Istanbul, Turkey, Koca, Dogan VM Med Pk Hosp, Dept Med Oncol, Kocaeli, Turkey, Basaran, Mert Istanbul Univ, Inst Oncol, Dept Med Oncol, Istanbul, Turkey |
| Jazyk: | angličtina |
| Rok vydání: | 2018 |
| Předmět: |
Oncology
Adult Male Cancer Research medicine.medical_specialty Prognostic factor Survival medicine.medical_treatment Nephrectomy Targeted therapy 03 medical and health sciences 0302 clinical medicine Renal cell carcinoma Internal medicine medicine Humans Carcinoma Renal Cell Protein Kinase Inhibitors Aged Retrospective Studies Aged 80 and over business.industry Brain Neoplasms Prognostic Factor digestive oral and skin physiology Renal Cell Carcinoma Targeted Therapy General Medicine Middle Aged medicine.disease Prognosis Kidney Neoplasms stomatognathic diseases 030220 oncology & carcinogenesis Brain Metastasis Female business 030217 neurology & neurosurgery Brain metastasis |
| Popis: | Background: The primary objective of our study was to examine the clinical outcomes and prognosis of patients with metastatic renal cell carcinoma (mRCC) with brain metastases (BMs) receiving targeted therapy. Patients and methods: Fifty-eight patients from 16 oncology centers for whom complete clinical data were available were retrospectively reviewed. Results: The median age was 57 years (range 30-80). Most patients underwent a nephrectomy (n = 41; 70.7%), were male (n = 42; 72.4%) and had clear-cell (CC) RCC (n = 51; 87.9%). Patients were treated with first-line suni-tinib (n = 45; 77.6%) or pazopanib (n = 13; 22.4%). The median time from the initial RCC diagnosis to the diagnosis of BMs was 9 months. The median time from the first occurrence of metastasis to the development of BMs was 7 months. The median overall survival (OS) of mRCC patients with BMs was 13 months. Time from the initial diagnosis of systemic metastasis to the development of BMs (2; pConclusions: The time from the initial diagnosis of systemic metastasis to the development of BMs (2) were independent risk factors for a poor prognosis. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|